Century Therapeutics Q2 net loss rises to $34.6 million from $32.5 million
Century Therapeutics reported a second-quarter 2026 net loss of $34.6 million, up from $32.5 million a year earlier, with no collaboration revenue in either period. Cash, cash equivalents and investments were $197.2 million at June 30, 2026, which the company says supports operations into 1Q 2029. For shareholders, the wider loss is offset in part by lower research and development and general and administrative spending, and the company reiterated an IND submission for CNTY-813 in the fourth quarter of 2026.
Key points
- Q2 2026 net loss was $34.6 million, versus a net loss of $32.5 million in Q2 2025; net loss per share was $0.17 versus $0.38, on 205.8 million weighted average shares versus 86.2 million.
- R&D expenses fell to $19.6 million from $26.9 million, and G&A expenses fell to $5.8 million from $7.8 million, which the company attributed to personnel and facility reductions.
- A $11.1 million loss on lease component termination was recorded in Q2 2026, and the six-month period showed a net loss of $56.2 million versus net income of $44.0 million a year earlier, when collaboration revenue was $109.2 million.
- The company stated that the CNTY-813 IND submission remains on track for 4Q 2026, with initial clinical data expected in 2H 2027.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.